LINC01213

Across TCGA pan-cancer cohorts, LINC01213 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of LINC01213’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LINC01213 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC01213 is over-expressed in tumor, although a few such as KIRC and THCA show the opposite, repressed pattern.

KIRC, LUAD, and THCA are the cancer types where LINC01213 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01213 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	−1.297	<.001	12	view →
LUAD	Male	All	+0.799	<.001	11	view →
THCA	Male	III,IV	−0.721	<.001	10	view →
KIRP	Male	All	−1.195	<.001	9	view →
BRCA	All	II,III,IV	+0.712	<.001	6	view →
LUSC	All	All	+0.534	.001	4	view →
KICH	Female	All	+1.469	.001	2	view →
UCEC	All	II,III,IV	−0.315	.049	2	view →
BLCA	All	IV	+1.811	.018	1	view →
KICH	Male	III,IV	−0.745	.035	1	view →
LIHC	Female	II,III,IV	+0.098	.033	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 10 lineages.

LINC01213–KIRC

Open the KIRC breakdown →